Big Peptide News: The FDA's Advisory Panel Just Voted "Yes" on 6 Peptides — Here's What Providers Need to Know

If you've been waiting to see which way the peptide winds would blow, the forecast just got a whole lot clearer.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) sat down to review seven popular peptides — and voted to recommend six of them for the Bulks List. In plain English? Six peptides just took a major step toward being legally available for pharmacy compounding again.

For providers, this is one of those "clear your inbox and pay attention" moments. For patients and the peptide-curious, it's the headline you've been seeing pop up everywhere. So let's break it all down — no jargon overload.

First, a 30-Second Refresher: What Even Is the PCAC?

The Pharmacy Compounding Advisory Committee is a group of independent experts that advises the FDA on which bulk drug substances pharmacies should be allowed to compound.

Think of them as the panel of judges. They watch the routine, hold up their scorecards, and make a recommendation. But here's the key part: the judges don't hand out the trophy. The FDA does. More on that in a minute.

The Big Vote: 6 Out of 7 Peptides Got the Nod

After two days of review, the committee voted to recommend these six peptides for Bulks List inclusion:

• BPC-157 — the buzzy one everyone's been talking about

• TB-500

• KPV

• Epitalon (also spelled Epithalon)

• Semax

• MOTS-c
  

The seventh peptide under review — DSIP (also called emideltide) — was the odd one out and did not get a recommendation.

Worth noting: several of these votes were close. BPC-157, TB-500, and KPV squeaked through 8–6 with one abstention, and MOTS-c passed 7–5. This wasn't a landslide — it was a real debate, which tells you how carefully the committee weighed the evidence.

Hold On — Does This Mean They're Available Right Now?

Short answer: not yet. And this is the part providers really need to understand before fielding a flood of patient questions.

A PCAC recommendation is a big deal, but it's a recommendation — not a final ruling. Here's the road that still lies ahead:

1. PCAC recommends (just happened)

2. The FDA reviews and makes the final call

3. Category 1 placement happens through a formal rulemaking process
   

That last step usually takes 8 to 12 months, so this is a "the ball is rolling" moment, not a "prescribe tomorrow" one. Setting that expectation with patients now will save everyone some confusion later.

Why Providers Should Care (Even If You Don't Prescribe Peptides Yet)

Peptide demand isn't slowing down — and there are a few clear reasons why:

• The GLP-1 ripple effect. As more patients explore GLP-1 medications, curiosity about complementary therapies has surged.

• The rise of proactive health. Patients aren't just treating problems anymore; they want to optimize energy, recovery, and longevity.

• A renewed focus on sourcing and safety. After years of gray-market products, patients want peptides from a legitimate, quality-controlled pharmacy — not a sketchy website.
  

Translation: your patients are already asking about this stuff. Being informed now means you're ready to have a credible, safe conversation when they do.

The Good News: You Don't Have to Wait to Offer Peptides

While those six peptides make their way through the FDA pipeline, there's a whole lineup of peptides that providers can prescribe today, including:

• GHK-Cu (facial serum and scalp solution)

• Gonadorelin injection

• Sermorelin (injection and ODT)

• Semaglutide and Tirzepatide combinations for metabolic support
  

So if a patient walks in curious about peptide therapy, the conversation doesn't have to end with "let's wait and see." There are evidence-based options ready to go right now.

The Bottom Line

The PCAC vote is a genuine win for patient access and a signal that responsible, pharmacy-compounded peptide therapy is being taken seriously. Six peptides cleared a meaningful hurdle — but the FDA still has the final say, and that process takes time.

For providers, the move is simple: stay informed, set realistic expectations with patients, and lean on peptides you can already prescribe safely today.

Want to Stay Ahead of the Peptide Curve?

This space is moving fast, and we're keeping a close eye on every update so you don't have to. If you'd like a clear, no-hype breakdown of which peptides you can prescribe right now — or a heads-up the moment the FDA makes its final call — we're here to help.

Reach out to our Compounding Business Specialist anytime to talk through your peptide options: Bberquist@gooddaypharmacy.com  Whether you're peptide-curious or ready to expand what you offer, a quick conversation can point you in the right direction.